Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,935 Million (Micro Cap)
6.00
NA
0.00%
-0.24
14.10%
0.84
Revenue and Profits:
Net Sales:
497 Million
(Quarterly Results - Jun 2025)
Net Profit:
137 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.96%
0%
5.96%
6 Months
3.59%
0%
3.59%
1 Year
7.08%
0%
7.08%
2 Years
-0.54%
0%
-0.54%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
JiangXi Tianxin Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.41%
EBIT Growth (5y)
-7.92%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.29
Sales to Capital Employed (avg)
0.45
Tax Ratio
15.62%
Dividend Payout Ratio
45.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.29%
ROE (avg)
18.62%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
0.84
EV to EBIT
4.18
EV to EBITDA
3.34
EV to Capital Employed
0.79
EV to Sales
1.26
PEG Ratio
0.17
Dividend Yield
NA
ROCE (Latest)
18.92%
ROE (Latest)
14.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
496.90
567.20
-12.39%
Operating Profit (PBDIT) excl Other Income
179.30
210.90
-14.98%
Interest
4.00
2.10
90.48%
Exceptional Items
2.70
0.00
Consolidate Net Profit
137.40
197.60
-30.47%
Operating Profit Margin (Excl OI)
271.00%
305.50%
-3.45%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -12.39% vs 5.66% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -30.47% vs -10.75% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,185.80
1,862.20
17.38%
Operating Profit (PBDIT) excl Other Income
774.30
550.40
40.68%
Interest
5.00
3.30
51.52%
Exceptional Items
1.60
-0.20
900.00%
Consolidate Net Profit
651.20
475.90
36.84%
Operating Profit Margin (Excl OI)
283.10%
220.30%
6.28%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.38% vs -18.42% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 36.84% vs -23.50% in Dec 2023
About JiangXi Tianxin Pharmaceutical Co., Ltd. 
JiangXi Tianxin Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






